Massimo Bresciani

Executive Director Scientific Operations & Board Member

Research Centre for Pharmaceutical Engineering & Geriatric Medicines Society

Massimo

About Massimo Bresciani

  • Executive Director Scientific Operations & Board Member at Research Centre for Pharmaceutical Engineering & Geriatric Medicines Society (www.geriatric-medicine.org/)
  • Scientific Adviser at Onteis (www.onteis.com)
  • Scientific Operations Director at Research Center Pharmaceutical Engineering GmbH (www.rcpe.at)
  • Scientific Advisor of Betterthis,” Building a value network around healthcare services”, www.betterthis.com/about.html (Paris, France)
  • Scientific and Business advisor for Nickel Technology Park Poznan (NTPP), http://www.ntpp.pl/english (Poznan, Poland)
  • Active member of Geriatric Medicine Society (non profit org, EU and USA) http://www.geriatric-medicine.org/

In his current position as Scientific Operations Director at Research Center Pharmaceutical Engineering GmbH he has the role of Business Unit Head, responsible for Business Development and Scientific Operation. Responsible for the whole RCPE projects and business opportunities.
Interim results: increased 3 times the average value of contract and collaboration with industries; added 16 international partner in RCPE pipeline (e.g. Pfizer UK, UCB, Novartis US, DS, Bayer Berlin etc); creation of a team focusing on advanced biopharmaceutics already recognized at international level (e.g. invited to support FDA Grant, 6 publication, 7 collaboration with industries); added 5 academic partners (e.g. Bath University, UCL university)

He has been working in the Pharmaceutical field for 25 years, 17 of which with supervisory/management responsibility. Director since 2009.

Prior joining RCPE in 2012, Massimo was Director of Chemistry Manufacturing & Control at Aptuit Verona, Italy (former GSK R&D center dedicated to preclinical and NeuroScience) . He played in that position the role of Business Unit Head (110 FTEs) with accountability for the P&L management (25M) and the Scientific Operations (API Development and Manufacturing, Product Development, Clinical Supply Operations, Respiratory Technology and Material Science). Results obtained after two years of operations: 18M Euro run rate, 40 active clients plus GSK, CMC organization stable and motivated.
Prior to joining Aptuit in July 2010, Massimo was a Pharmaceutical Development Manager in GlaxoSmithKline.

Prior to joining Aptuit in July 2010, Massimo was a Pharmaceutical Development Manager in GlaxoSmithKline.

During his GSK period he acted as a CMC Leader in charge of the development of NCEs (from pre-CS to Phase IIb) in the neurology/psychiatry and oncology therapeutics field; it is worthwhile mentioning that he was appointed as leader for some strategic initiatives like the “Simplification paradigm of the Formulation Strategy of Oral Dosage Forms in Early Phases”.

Massimo joined GSK in 2005 with 15 year experience in pharmaceutical dosage forms development and drug delivery systems.
His career started in 1989 in a “start-up” Drug Delivery Company (i.e. VECTORPHARMA) founded in 1988 and mainly targeted to exploit the potential for applying physical chemical and kinetics concepts to advanced drug delivery.

His career and expertise have been developed in different Drug Delivery, CRO and Specialty Pharma companies (Vectorpharma, Recordati, Eurand, GSK and Aptuit), covering different roles in different field of business: Drug Delivery Systems development, NCEs and Generics Development (R&D), Industrialization/Production (secondary Mfg) and Project Management.

He has a consolidated multidisciplinary expertise in pharmaceutical development of New Chemical Entities (NCEs) from lead optimisation/candidate selection throughout all the preclinical and clinical phases (regulatory submissions included in UK, USA/Canada and RoW) to PoC and beyond and he is used to work at the interfaces with all the other chemical, pharmacological, biological, toxicological and clinical components in a strongly integrated R&D context.

The translational research (from bench to bedside) is a paradigm that is familiar to him and his expertise in biopharmaceutics was definitely built up with the iterative evaluation of in vitro/in vivo data and animal/human volunteers/patients data.

Member of Geriatric Medicine Society and active player in the field or Patient Compliance/Adherence

Proven track record of overachievement against revenue , scientific implementation and growth goals (profit focused and customer oriented).

Author and co-author of scientific papers and international patents.

Diploma in Analytical Chemistry.